Familial gastric cancer: Genetics, diagnosis, and management

Surgical Oncology Clinics of North America

Volumn 21, Issue 1, 2012, Pages 35-56

  Blair, Vanessa R ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WHANGAREI HOSPITAL   (New Zealand)

Author keywords

E cadherin; Familial gastric cancer; Hereditary diffuse gastric cancer; Prophylactic gastrectomy

Indexed keywords

CHLOROPHYLL; CYCLOOXYGENASE 2 INHIBITOR;

AGE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; DISEASE ASSOCIATION; DNA METHYLATION; E CADHERIN GENE; EARLY CANCER; FAMILIAL CANCER; FAMILY HISTORY; FEMALE INFERTILITY; FOLLOW UP; GASTROSCOPY; GENE FUNCTION; GENE MUTATION; GENETIC MODEL; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HELICOBACTER INFECTION; HEREDITARY DIFFUSE GASTRIC CANCER; HISTOPATHOLOGY; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK FACTOR; STOMACH CANCER; STOMACH CARCINOGENESIS; SURGICAL MORTALITY; SURGICAL RISK; TOTAL STOMACH RESECTION;

CADHERINS; CONSENSUS; DNA MUTATIONAL ANALYSIS; FEMALE; GASTRECTOMY; GASTROSCOPY; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; INFERTILITY, FEMALE; MALE; NEOPLASM STAGING; PEDIGREE; PENETRANCE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS; WEIGHT LOSS;

EID: 82955214538     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.09.003     Document Type: Review

References (93)

1. Lugli A., Zlobec I., Singer G., et al. Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nat Clin Pract Gastroenterol Hepatol 2007, 4:52.
2. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402.
3. Guilford P., Hopkins J., Grady W., et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999, 14:249.
4. Jones E. Familial gastric cancer. N Z Med J 1964, 63:287.
5. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965, 64:31.
6. Shimoyama Y., Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. Cancer Res 1991, 51:2185.
7. Becker K., Atkinson M., Reich U., et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994, 54:3845.
8. Machado J.C., Soares P., Carneiro F., et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999, 79:459.
9. Chan J., Wong C. Loss of E-cadherin is the fundamental defect in diffuse-type gastric cancer and infiltrating lobular carcinoma of the breast. Adv Anat Pathol 2001, 8:165.
10. Kaurah P., MacMillan A., Boyd N., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297:2360.
11. Caldas C., Carneiro F., Lynch H.T., et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999, 36:873.
12. Blair V., Martin I., Shaw D., et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006, 4:262-275.
13. Lynch H.T., Grady W., Lynch J.F., et al. E-cadherin mutation-based genetic counseling and hereditary diffuse gastric carcinoma. Cancer Genet Cytogenet 2000, 122:1.
14. Pharoah P., Guilford P., Caldas C., et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121:1348.
15. Chun Y.S., Lindor N.M., Smyrk T.C., et al. Germline E-cadherin mutations: is prophylactic gastrectomy indicated?. Cancer 2001, 92:181.
16. Fitzgerald R.C., Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004, 53:775.
17. Lewis F.R., Mellinger J.D., Hayashi A., et al. Prophylactic total gastrectomy for familial cancer. Surgery 2001, 130:612.
18. Carneiro F., Huntsman D.G., Smyrk T.C., et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004, 203:681.
19. Charlton A., Blair V., Shaw D., et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004, 53:814.
20. Huntsman D.G., Carneiro F., Lewis F.R., et al. Early gastric cancer in young asymptomatic carriers of germline E-cadherin mutations. N Engl J Med 2001, 344:1904.
21. Shaw D., Blair V., Framp A., et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?. Gut 2005, 54:461.
22. Fitzgerald R., Hardwick R., Huntsman D., et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436.
23. Blair V., Parry S. Familial gastric cancer. A guide to cancer genetics in clinical practice 2008, TFM Publishing Ltd, Shrewsbury (United Kingdom). S. Clark (Ed.).
24. Oliveira C., Bordin M.C., Grehan N., et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Human Mutation 2002, 19:510.
25. Shinmura K., Kohno T., Takahashi M., et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis 1999, 20:1127.
26. Brooks-Wilson A.R., Kaurah P., Suriano G., et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004, 41:508.
27. Suriano G., Oliveira C., Ferreira P., et al. Identification of CDH-1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003, 12:575.
28. La Vecchia C., Negri E., Franceschi S., et al. Family history and the risk of stomach and colorectal cancer. Cancer 1992, 70:50.
29. Park J.G., Yang H.K., Kim W.H., et al. Report on the first meeting of the international collaborative group on hereditary gastric cancer. J Natl Cancer Inst 2000, 92:1781.
30. Zanghieri G., Di Gregorio C., Sacchetti C., et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 1990, 66:2047.
31. Kjartansson I., Jonsson Eldon B., Arinbjarnarson S., et al. Genetic epidemiologic aspects of gastric cancer in Iceland. J Am Coll Surg 2002, 195:181.
32. Furnival C. Relevant risk for women with BRCA1 and BRCA2 mutations. ANZ J Surg 2007, 77:309.
33. Pedrazzani C., Corso G., Marrelli D., et al. E-cadherin and hereditary diffuse gastric cancer. Surgery 2007, 142:645.
34. Barber M., Murrell A., Ito Y., et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008, 216:295.
35. Oliveira C., Seruca R., Carneiro F. Genetics, pathology and clinics of familial gastric cancer. Int J Surg Pathol 2006, 14:21.
36. Schrader K., Huntsman D. Hereditary diffuse gastric cancer. Cancer Genet 2010, 155:33.
37. Guilford P.J., Blair V., More H., et al. A short guide to hereditary diffuse gastric cancer. Hered Cancer Clin Pract 2007, 5:183.
38. Suriano G., Seixas S., Rocha J., et al. A model to infer the pathogenic significance of CDH1 germline missense variants. J Med Genet 2006, 84:1023-1031.
39. Jarvinen H.J. Genetic testing for polyposis: practical and ethical aspects. Gut 2003, 52:ii19.
40. Blair V.R. Hereditary diffuse gastric cancer: of mice and man, in department of surgery 2009, University of Auckland, Auckland (New Zealand).
41. Rogers W., Dobo E., Norton J., et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008, 32:799.
42. Humar B., Blair V., Charlton A., et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009, 69(5):2050-2056.
43. Guilford P., Humar B., Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010, 13(1):1-10.
44. Humar B., Fukuzawa R., Blair V., et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007, 67:2480.
45. Statement of American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996, 14:1730.
46. Clarke A. Clinical Genetics Society: the genetic testing of children: report of a working party of the Clinical Genetics Society (A Clarke, chairman). J Med Genet 1994, 31:785.
47. Robertson S., Savulescu J. Is there a favour of predictive genetic testing in young children?. Bioethics 2001, 15:26.
48. Codori A.M., Zawacki K.L., Petersen G.M., et al. Genetic testing for hereditary colorectal cancer in children: long-term psychological effects. Am J Med Genet A 2003, 116:117.
49. Michie S., Bobrow M., Marteau T. Predictive genetic testing in children and adults: a study of emotional impact. J Med Genet 2001, 38:519.
50. McConkie-Rosell A., Spiridigliozzi G.A. " Family Matters": a conceptual framework for genetic testing in children. J Genet Couns 2004, 13:9.
51. Clarke A. Parents' responses to predictive genetic testing in their children. J Med Genet 1997, 34:174.
52. Michie S. Reply: parents' responses to predictive genetic testing in their children. J Med Genet 1997, 34:174.
53. Shaw D., Blair V., Martin I. Chromoendoscopic surveillance in a Maori kindred genotypically predisposed to hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy 2003, [abstract: M1839], Digestive Diseases Week, Orlando (FL).
54. Brennan M. Safety in numbers. Br J Surg 2004, 91:653.
55. Lehnert T., Buhl K. Techniques of reconstruction after total gastrectomy for cancer. Br J Surg 2004, 91:528.
56. Liedman B. Symptoms after total gastrectomy on food intake, body composition, bone metabolism and quality of life in gastric cancer patients-is reconstruction of a reservoir worthwhile?. Nutrition 1999, 15:677.
57. McCulloch P., Nita M., Kazi H., et al. Extended versus limited lymph node dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004, 4. CD001964.
58. Fein M., Fuchs K., Thalheimer A., et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg 2008, 247:759.
59. Everett S., Axon A. Early gastric cancer in Europe. Gut 1997, 41:142.
60. Barr H., Greenall M. Carcinoma of the stomach. Oxford textbook of surgery 2000, vol. 2:1313. Oxford University Press, Oxford (UK). P.J. Morris, W.C. Wood (Eds.).
61. Kim J.P., Kim S.C., Yang H.K. Prognostic significance of signet ring cell carcinoma of the stomach. Surg Oncol 1994, 3:221.
62. Hyung W.J., Noh S.H., Lee J.H., et al. Early gastric carcinoma with signet ring cell histology. Cancer 2002, 94:78.
63. Maehara Y., Sakaguchi Y., Moriguchi S., et al. Signet ring cell carcinoma of the stomach. Cancer 1991, 69:1645.
64. Otsuji E., Yamaguchi T., Sawai K., et al. Characterization of signet ring cell carcinoma of the stomach. J Surg Oncol 1998, 67:216.
65. Penfold J. Growth and its abnormalities. Practical paediatrics 1994, 507. Churchill Livingstone, London (UK). 3rd edition. M.J. Robinson, D.M. Roberton (Eds.).
66. Berx G., Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001, 3:289.
67. Kriege M., Brekelmans C., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427.
68. Leach M., Boggis C., Dixon A., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769.
69. Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003, 56:1.
70. Suriano G., Yew S., Ferreira P., et al. Characterisation of a recurrent germ line mutation of the E-cadherin Gene: Implications for genetic testing and clinical management. Human Cancer Biology 2005, 11(15):5401-5409.
71. More H., Humar B., Weber W., et al. Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Human Mutation 2007, 28(2):203-211.
72. Richards F.M., McKee S.A., Rajpar M.H., et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Human Molecular Genetics 1999, 8(4):607-610.
73. Moran C.J., Joyce M., McAnena O.J. CDH1 associated gastric cancer: a report of a family and review of the literature. European Journal of Surgical Oncology 2005, 31(3):259-264. [review].
74. Humar B., Toro T., Graziano F., et al. Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Human Mutation 2002, 19(5):518-525.
75. Gayther S.A., Gorringe K.L., Ramus S.J., et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Research 1998, 58(18):4086-4089.
76. Dussaulx-Garin L., Blayau M., Pagenault M., et al. A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol 2001, 13:711-715.
77. Keller G., Vogelsang H., Becker I., et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. American Journal of Pathology 1999, 155(2):337-342.
78. Frebourg T., Oliveira C., Hochain P., et al. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. Journal of Medical Genetics 2006, 43(2):138-142.
79. Kaurah P., MacMillan A., Boyd N., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297(21):2360-2372.
80. Yoon K., Ku J., Yang H., et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 1999, 44:177-180.
81. Ikonen T., Matikainen M., Mononen N., et al. Association of E-cadherin germ-line alterations with prostate cancer. Clin Cancer Res 2001, 7(11):3465-3471.
82. Oliveira C., Bordin M.C., Grehan N., et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in Hereditary Diffuse Gastric Cancer kindred. Human Mutation 2002, 19(5):510-517.
83. Jonsson B.A., Bergh A., Stattin P., et al. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002, 98(6):838-843.
84. Roviello F., Corso G., Pedrazzani C., et al. Hereditary diffuse gastric cancer and E-cadherin: description of the first germline mutation in an Italian family. European Journal of Surgical Oncology 2007, 33(4):448-451.
85. Wang H.D., Ren J., Zhang L. CDH1 germline mutation in hereditary gastric carcinoma. World J Gastroenterol 2004, 10:3088-3093.
86. Jiang Y., Wan Y.L., Wang Z.J., et al. Germline E-cadherin gene mutation screening in familial gastric cancer kindreds. Chinese Journal of Surgery 2004, 42(15):914-917. [in Chinese].
87. Rodriguez-Sanjuan J.C., Fontalba A., Mayorga M., et al. A novel mutation in the E-cadherin gene in the first family with hereditary diffuse gastric cancer reported in Spain. European Journal of Surgical Oncology 2006, 32:1110-1113.
88. Keller G., Vogelsang H., Becker I., et al. Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 2004, 41(6):e89.
89. Oliveira C., Ferreira P., Nabais S., et al. E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. European Journal of Cancer 2004, 40(12):1897-1903.
90. Yabuta T., Shinmura K., Tani M., et al. E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. Int J Cancer 2002, 101(5):434-441.
91. Bacani J.T., Soares M., Zwingerman R., et al. CDH1/E-cadherin germline mutations in early-onset gastric cancer. Journal of Medical Genetics 2006, 43(11):867-872.
92. Ascano J.J., Frierson H., Moskaluk C.A., et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Modern Pathology 2001, 14(10):942-949.
93. Masciari S., Larsson N., Senz J., et al. Germline E-cadherin mutations in familial lobular breast cancer. Journal of Medical Genetics 2007, 44(11):726-731.